Clasado Biosciences (‘Clasado’) has shared comment on the increasing demand for sustainability across life sciences sectors.
The business has seen a significant shift in market priorities from both its own perspective as a supplier, and through its own finished consumer range of prebiotic supplements, Bimuno®. It believes that a major change is on the cards, which will see pharmaceuticals, commercial health and wellbeing, functional ingredients and biomedical technology companies leverage sustainability as a competitive edge.
Dr Frederic Narbel, Vice President of Sales B2B at Clasado Biosciences, explains: “We have all seen the global upswing in focus on environmental and social governance (ESG). Consumers want to know that the brands and products they choose are making a tangible and meaningful difference to the world around us.
“While the life sciences industry has made quiet gains in sustainability through supply chains and packaging, it typically hasn’t been a key focus in the same way as categories such as FMCG, food and beverages. After all, products in this category are typically chosen for a specific health need and as such are often selected by efficacy and scientific backing rather than sustainability credentials.
“We are expecting this to change significantly as we press forward. When we look ahead to national initiatives such as the UK’s Green Claims Code and the race to Net Zero, it’s clear that no industry can afford to ignore the topic today. ‘Green’ manufacturing in life sciences needs to be front and centre, not just in terms of persuading the consumer, but in securing the long-term success of the industry.”
Clasado Biosciences focuses its scientific and commercial activities around careful control of the planet’s resources. Alongside a constantly evolving supply chain and regular auditing of procurement, manufacturing and packaging, the business has an ambitious long-term sustainability plan to ensure the business plays its part in creating positive environmental and social change.
The business is best known as the developer of multi award-winning prebiotic ingredient, Bimuno®. The galactooligosaccharide (GOS) is the most studied ingredient of its kind, supported by over 100 scientific publications, including more than 20 clinical trials.
Dr Narbel concludes: “The consumer health industry – and indeed the wider life sciences category – has a key role to play in supporting the health of the planet as much as the people that live on it; and we’re set for an exciting period of real, landmark change.
“Together, we’re moving sustainability from a ‘nice to have’ or a box ticking exercise to a core component of the industry. The life sciences sector, including our own R&D team at Clasado, hosts some of the most innovative minds, so it’s exciting to see where the path to more sustainable consumer health science could take us.”
To find out more about Clasado Biosciences, please visit www.clasado.com